Table 2 Baseline demographic and clinical characteristics of the study participants in the across lipid-derived phenogroups
Variables | Phenogroup 1 (n = 415) | Phenogroup 2 (n = 496) | Phenogroup 3 (n = 444) | P value |
|---|---|---|---|---|
Age, years | 63.3 (12.5) | 67.1 (11.6) | 59.5 (12.5) | < 0.001 |
Male, sex | 349 (84.1%) | 350 (70.6%) | 377 (84.9%) | < 0.001 |
Previous event | ||||
 Myocardial infarction | 19 (4.6%) | 19 (3.8%) | 18 (4.1%) | 0.84 |
 PCI | 13 (3.1%) | 17 (3.4%) | 9 (2.0%) | 0.42 |
Diabetes | 91 (21.9%) | 90 (18.1%) | 108 (24.3%) | 0.061 |
Hypertension | 219 (52.8%) | 262 (52.8%) | 219 (49.3%) | 0.49 |
Dyslipidemia | 46 (11.1%) | 30 (6.0%) | 64 (14.4%) | < 0.001 |
Chronic kidney disease | 19 (4.6%) | 11 (2.2%) | 10 (2.3%) | 0.084 |
Smoking status | 301 (72.5%) | 293 (59.1%) | 327 (73.6%) | < 0.001 |
Time to balloon, h | 6.0 (4.0–11.0) | 6.0 (3.5–11.0) | 5.0 (3.0–9.0) | 0.062 |
SBP, mmHg | 123.3 (25.5) | 124.9 (26.3) | 127.0 (23.7) | 0.092 |
HR, bpm | 81.9 (19.2) | 81.0 (19.3) | 83.2 (16.8) | 0.18 |
BMI, Kg/m2 | 24.0 (3.5) | 23.0 (3.7) | 25.1 (3.4) | < 0.001 |
Culprit artery | Â | Â | Â | 0.02 |
 LAD | 183 (44.1%) | 278 (56.0%) | 227 (51.1%) |  |
 LCX | 44 (10.6%) | 62 (8.1%) | 47 (10.6%) |  |
 RCA | 178 (42.9%) | 169 (34.1%) | 157 (35.4%) |  |
 LM | 4 (1.0%) | 1 (0.2%) | 3 (0.7%) |  |
 Multivessel | 6 (1.4%) | 8 (1.6%) | 10 (2.2%) |  |
Gensini score | 56.3 (23.7) | 53.3 (25.2) | 55.2 (26.1) | 0.20 |
Killip class (> II) | 116 (28.0%) | 142 (28.6%) | 100 (22.5%) | 0.092 |
Postprocedural TIMI (< II) | 29 (7.0%) | 33 (6.7%) | 25 (5.6%) | 0.71 |
Hb, g/L | 134.6 (19.2) | 141.5 (20.7) | 137.9 (20.2) | < 0.001 |
HbA1c, % | 6.6 (1.7) | 6.4 (1.6) | 6.9 (1.7) | < 0.001 |
Creatinine, μmol/L | 96.6 (33.8) | 81.8 (42.7) | 81.0 (38.8) | < 0.001 |
FT3, pg/ml | 2.87 (0.51) | 2.87 (0.94) | 2.98 (0.68) | 0.004 |
FT4, ng/dl | 0.92 (0.21) | 0.95 (0.39) | 0.89 (0.16) | 0.002 |
hsTSH, μIU/ml | 0.92 (0.57–1.7) | 0.98 (0.54–1.68) | 0.98 (0.53–1.57) | 0.99 |
cTNI, ug/L | 98.4 (9.8–473.3) | 74.7 (6.9–462.8) | 90.1 (9.1–471.0) | 0.35 |
NT-proBNP | 0.96 (0.34–186) | 1.33 (0.34–169) | 0.70 (0.27–162) | 0.16 |
LVEF, % | 55.5 (7.1) | 54.3 (8.1) | 55.3 (7.4) | 0.059 |
Aspirin | 406 (97.8%) | 489 (98.6%) | 444 (100.0%) | 0.003 |
Statin | 415 (100.0%) | 494 (99.6%) | 442 (99.5%) | 0.56 |
Beta-blocker | 336 (81.0%) | 403 (81.3%) | 386 (86.9%) | 0.024 |
Diuretics | 180 (43.4%) | 219 (44.2%) | 153 (34.5%) | 0.004 |